All Updates

All Updates

icon
Filter
Product updates
EDX Medical launches new products and services for assessing hereditary cancer risk
Precision Medicine
Jun 20, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 20, 2024

EDX Medical launches new products and services for assessing hereditary cancer risk

Product updates

  • EDX Medical has revealed its new suite of products and services designed to evaluate hereditary cancer risk. The tests are developed based on comprehensive hereditary gremlin cancer testing designed to test the risk of cancer of family members of diagnosed cancer patients.

  • Its pan-cancer test is claimed to have 99% sensitivity and the ability to identify mutations in 70 genes known to be associated with cancers such as prostate, breast, colorectal, pancreatic, and ovarian cancer. The tests will be made available through specific NHS Genetic and Genomic Testing Centres and certain private healthcare providers in late 2024. The company will also be providing support services for healthcare professionals who will be using the tests.

  • UK-based EDX Medical Group is a digital diagnostics company focused on developing and delivering testing solutions. Its primary offerings include digital diagnostic products and services targeting cancer, cardiovascular disease, neurology, and infectious diseases. The company's approach combines advanced biological and digital technologies to improve disease risk detection and personalize disease management efficiently​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.